In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OptumRx Inc.

http://www.optumrx.com

Latest From OptumRx Inc.

Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care

In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.

Biosimilars Reimbursement

Patient-Doc Task Force Building Legal Case Against Alternative Funding Programs

From illegal importation under FDCA to possible ERISA, HIPAA and ACA violations – a task force led by CancerCare is pushing regulatory agencies with levers to go after employer plans use of alternative funding programs for specialty drugs, which they say violate multiple federal laws. 

Reimbursement Pricing Debate

‘Transparency-Rx’: Meet The PBM Execs Breaking Rank And Backing Reforms

New coalition of smaller PBMs champions federal policies requiring ‘100% pass-through’ of rebates, with PBMs then paid by a flat, disclosed fee.

Pricing Debate Leadership

Stock Watch: Merck & Co’s Anti-IRA Litigation Is A Risky Gambit

There are many new pressures on biopharmaceutical profitability but will Merck & Co’s attempt to reverse the drug pricing aspects of the Inflation Reduction Act just divert costs to patients?

Stock Watch Pricing Debate
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
UsernamePublicRestriction

Register